This Article Full Text (PDF) All Versions of this Article: 0960327109346789v1 28/10/619    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Kobayashi, T. Articles by Onoue, M. PubMed PubMed Citation Articles by Kobayashi, T. Articles by Onoue, M. Social Bookmarking                         What's this?

Safety of a novel galacto-oligosaccharide: Genotoxicity and repeated oral dose studies

Yakult Central Institute for Microbiological Research, Safety Research Center, Kunitachi-shi, Tokyo, Japan, toshihide-kobayashi{at}yakult.co.jp

N. Yasutake

Yakult Central Institute for Microbiological Research, Safety Research Center, Kunitachi-shi, Tokyo, Japan

K. Uchida

Yakult Central Institute for Microbiological Research, Safety Research Center, Kunitachi-shi, Tokyo, Japan

W. Ohyama

Yakult Central Institute for Microbiological Research, Safety Research Center, Kunitachi-shi, Tokyo, Japan

K. Kaneko

Yakult Central Institute for Microbiological Research, Safety Research Center, Kunitachi-shi, Tokyo, Japan

M. Onoue

Yakult Central Institute for Microbiological Research, Safety Research Center, Kunitachi-shi, Tokyo, Japan

A series of safety tests were undertaken on a novel galacto-oligosaccharide (GOS) produced from lactose by a two-step enzymatic process involving Sporobolomyces singularis and Kluyveromyces lactis. Bacterial reverse mutation and chromosomal aberration tests, with or without metabolic activation, were performed. These tests showed no mutagenesis in the Ames assay or in Escherichia coli WP2uvrA, and no chromosomal aberrations in cultured fibroblast cells from Chinese hamster lungs (CHL/IU). Micronuclei were not induced in the reticulocytes of mouse peripheral blood following oral administration of GOS. In a 90-day repeated oral dose toxicity study in rats, GOS was administered at 0, 500, 1000 and 2000 mg/kg to male and female Sprague-Dawley rats. There were no GOS-related changes in clinical signs, body weight, water intake, feed intake, urinalysis, ophthalmology, haematology, blood chemistry, organ weights, gross pathology or histopathology in any of the treatment groups compared to the control group. The no observed adverse effect level (NOAEL) of GOS was at least 2000 mg/kg/day in both males and females.

Key Words: A novel galacto-oligosaccharide • GOS • safety • repeated oral dose toxicity • genotoxicity

This version was published on October 1, 2009

Human & Experimental Toxicology, Vol. 28, No. 10, 619-630 (2009)
DOI: 10.1177/0960327109346789


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?